Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOEARH)

Drug Name
AZD2014 Drug Info
Synonyms
AZD2014; 1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)
Cross-matching ID
PubChem CID
25262792
ChEBI ID
CHEMBL2336325
CAS Number
CAS 1009298-59-2
TTD Drug ID
D0Z2UQ
INTEDE Drug ID
DR1837

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Sulfur metabolism 1.95 8.73e-3 9/10 (90%) MPST;TST;ETHE1;...
ECM-receptor interaction 1.89 2.62e-2 80/88 (90.91%) FN1;ITGB5;THBS3;...
Adherens junction 1.83 2.04e-2 63/71 (88.73%) MET;ERBB2;IGF1R;...
Notch signaling pathway 1.79 1.96e-2 49/59 (83.05%) JAG1;TLE4;RFNG;...
Focal adhesion 1.77 1.92e-2 180/201 (89.55%) MET;FN1;MYLK;...
Calcium signaling pathway 1.72 3.06e-2 213/240 (88.75%) SLC25A6;MET;PLCB4;...
Wnt signaling pathway 1.70 3.24e-2 124/166 (74.7%) MYC;PLCB4;SFRP1;...
Arrhythmogenic right ventricular cardiomyopathy 1.68 3.93e-2 70/77 (90.91%) ITGB5;ITGA3;ITGB1;...
Other glycan degradation 1.67 4.27e-2 13/18 (72.22%) HEXA;FUCA1;MAN2C1;...
Spliceosome -1.64 4.21e-2 101/150 (67.33%) PRPF38B;RBM22;DHX8;...
Glycolysis / Gluconeogenesis -1.65 4.13e-2 56/67 (83.58%) TPI1;ENO1;DLAT;...
Folate biosynthesis -1.68 2.97e-2 23/26 (88.46%) MOCOS;QDPR;CBR1;...
Cysteine and methionine metabolism -1.70 2.88e-2 43/50 (86%) GSS;LDHC;DNMT1;...
Fructose and mannose metabolism -1.71 2.78e-2 30/33 (90.91%) TPI1;HK2;ALDOA;...
Huntington disease -1.72 2.73e-2 233/306 (76.14%) NDUFA9;PSMD7;CASP3;...
IL-17 signaling pathway -1.74 2.52e-2 84/94 (89.36%) CASP3;MMP3;CXCL5;...
Epstein-Barr virus infection -1.74 2.72e-2 189/202 (93.56%) MAPK10;TBK1;CDKN1A;...
Terpenoid backbone biosynthesis -1.77 2.18e-2 18/22 (81.82%) MVD;DHDDS;MVK;...
PPAR signaling pathway -1.88 2.07e-3 66/74 (89.19%) ACSL4;APOC3;ACAA1;...
Spinocerebellar ataxia -1.90 2.28e-3 128/143 (89.51%) RORA;PSMC5;MAPK10;...
Glycine, serine and threonine metabolism -1.91 2.53e-3 31/40 (77.5%) SRR;SHMT1;CBS;...
Prion disease -1.92 2.85e-3 209/273 (76.56%) ATP5F1B;NDUFS8;MAPK1;...
DNA replication -1.92 3.25e-3 34/36 (94.44%) RFC1;POLD2;RPA2;...
Parkinson disease -1.92 1.90e-3 176/249 (70.68%) NDUFA9;PSMD7;CASP3;...
Amyotrophic lateral sclerosis -1.93 2.28e-3 267/364 (73.35%) NDUFS3;BID;NDUFAB1;...
Protein processing in endoplasmic reticulum -1.95 2.85e-3 127/171 (74.27%) MAPK10;DNAJC3;DNAJC1;...
Legionellosis -1.99 0.00e+0 51/57 (89.47%) CASP1;VCP;CASP8;...
Steroid biosynthesis -2.33 0.00e+0 19/20 (95%) LBR;HSD17B7;NSDHL;...
Proteasome -2.81 0.00e+0 44/46 (95.65%) PSMC3;PSMC1;PSMD8;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H